[cycEVA study: case control study measuring influenza vaccine effectiveness in Spain, 2008-2013]

Rev Esp Salud Publica. 2014 Oct;88(5):601-11. doi: 10.4321/S1135-57272014000500005.
[Article in Spanish]

Abstract

Background: In Spain, influenza vaccine effectiveness (EV) is estimated since 2008-09 season through the cycEVA case-control study, the Spanish component of the European I-MOVE (Monitoring Influenza Vaccine Effectiveness in the EU/EEA) network. We aimed at describing cycEVA performance in its five consolidated editions 2008/09 -; 2012/13.

Methods: During the study period the following indicators were analysed: 1) the participation of sentinel general practitioners and pediatricians (MP), 2) the population studied and the study period, 3) the data quality and 4) the dissemination of the cycEVA results. Trend analysis of the indicators was done using the Cochran-Armitage test to compute the Annual Percentage Change (PCA).

Results: The number of participating MP increased from 164 in 2008-09 to 246 in the following editions. The percentage of MP recruiting at least one patient increased significantly annually (PCA = 15.33%). The percentage of recruited patients included into the analysis increased (PCA=5.91%) from 77% in 2008-09 to more than 95% in the following editions. The percentage of cycEVA patients contributing to the I-MOVE study ranged between 23% and 30% in the pilot and 2011-12 editions respectively.. Final results were disseminated in quartile 2 peer-reviewed journals and 2010-11 and 2011-12 preliminary EV estimates were published in quartile 1 journals. cycEVA publications received 97 citations.

Conclusion: cycEVA study achieved more quality information, timely EV estimates and a higher impact of the results.

MeSH terms

  • Adult
  • Case-Control Studies
  • Female
  • Humans
  • Influenza Vaccines / therapeutic use*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Male
  • Middle Aged
  • Population Surveillance*
  • Publishing
  • Seasons
  • Spain / epidemiology

Substances

  • Influenza Vaccines